Home › Compare › UVRBF vs ABBV
UVRBF yields 2.95% · ABBV yields 3.06%● Live data
📍 UVRBF pulled ahead of the other in Year 9
Combined, UVRBF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of UVRBF + ABBV for your $10,000?
Universal Robina Corporation operates as a branded food product company in the Philippines and internationally. It operates through three segments: Branded Consumer Foods, Agro-Industrial Products, and Commodity Food Products. The Branded Consumer Foods segment manufactures and distributes a range of salty snacks, chocolates, candies, biscuits, packed cakes, beverages, instant noodles, pasta, and bakery products, as well as ready-to-drink tea products. This segment also manufactures bi-axially oriented polypropylene films that are used in packaging; and flexible packaging materials for various branded products. The Agro-Industrial Products segment engages in hog and poultry farming; and manufacturing and distributing animal feeds, glucose, and soya products, as well as animal health products. The Commodity Food Products segment is involved in sugar milling and refining, as well as flour milling and pasta manufacturing activities. This segment is also involved in renewable energy business. The company sells its branded food products to supermarkets, wholesalers, convenience stores, trading companies, and distributors, as well as consumer food products through retailers and distributors to approximately 250,000 retail outlets. Its licensed brands include Nissin Cup Noodles, Nissin Yakisoba Instant Noodles and Nissin Pasta Express, Vitasoy, Calbee and B'lue, and others. The company was incorporated in 1954 and is headquartered in Quezon City, the Philippines. Universal Robina Corporation is a subsidiary of JG Summit Holdings, Inc.
Full UVRBF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.